Kiniksa Pharmaceuticals

Update in progress

KNSA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies in the United States, the United Kingdom, and internationally. Its lead product, ARCALYST, traps IL-1α and IL-1β for recurrent pericarditis and cardiac sarcoidosis. It is developing KPL-387 (a fully human IgG2 antibody) in Phase 2/3 for recurrent pericarditis and KPL-116 (an IgG2 antibody) in preclinical studies. Formerly Kiniksa Ltd, renamed in June 2024; founded in 2015 and based in London.

Company score

Sentiment: 0.12; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.08; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive